CA2457056A1 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor - Google Patents

Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor Download PDF

Info

Publication number
CA2457056A1
CA2457056A1 CA002457056A CA2457056A CA2457056A1 CA 2457056 A1 CA2457056 A1 CA 2457056A1 CA 002457056 A CA002457056 A CA 002457056A CA 2457056 A CA2457056 A CA 2457056A CA 2457056 A1 CA2457056 A1 CA 2457056A1
Authority
CA
Canada
Prior art keywords
metastasis
recurrence
inhibiting
preventing
malignant tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002457056A
Other languages
French (fr)
Other versions
CA2457056C (en
Inventor
Takayuki Kawaguchi
Satoshi Okuno
Toshiro Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2457056A1 publication Critical patent/CA2457056A1/en
Application granted granted Critical
Publication of CA2457056C publication Critical patent/CA2457056C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The present invention is directed to a pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof. Preferred active substances are camptothecin derivatives.
CA002457056A 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor Expired - Fee Related CA2457056C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
JP2001-249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor

Publications (2)

Publication Number Publication Date
CA2457056A1 true CA2457056A1 (en) 2003-02-27
CA2457056C CA2457056C (en) 2008-07-22

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457056A Expired - Fee Related CA2457056C (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Country Status (18)

Country Link
EP (1) EP1418947A1 (en)
KR (1) KR20040027972A (en)
CN (1) CN100372570C (en)
AR (1) AR035137A1 (en)
AU (1) AU2002328093B2 (en)
BR (1) BR0212036A (en)
CA (1) CA2457056C (en)
HU (1) HUP0401351A3 (en)
IL (1) IL160148A0 (en)
MX (1) MXPA04001599A (en)
NO (1) NO20041194L (en)
NZ (1) NZ530947A (en)
PL (1) PL368319A1 (en)
RU (1) RU2275913C2 (en)
TW (1) TWI313609B (en)
UA (1) UA75450C2 (en)
WO (1) WO2003015826A1 (en)
ZA (1) ZA200400917B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (en) * 2007-03-29 2009-07-03 Proteins & Peptides Man DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS
CN102124096B (en) 2008-07-16 2014-10-22 儿童医疗中心有限公司 Organ mimic device with microchannels and methods of use and manufacturing thereof
KR20190042747A (en) * 2011-06-02 2019-04-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods and uses for ex vivo tissue culture systems
PL221351B1 (en) 2012-03-14 2016-03-31 Politechnika Warszawska Method for obtaining polysaccharide nanoparticles
NZ740948A (en) 2012-10-11 2019-11-29 Daiichi Sankyo Co Ltd Glycinamide derivatives and production methods thereof
ES2782248T3 (en) * 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure
KR102275925B1 (en) 2014-01-31 2021-07-12 다이이찌 산쿄 가부시키가이샤 Anti-her2 antibody-drug conjugate
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN116059395A (en) 2015-06-29 2023-05-05 第一三共株式会社 Method for selectively producing antibody-drug conjugates
TW201828993A (en) 2016-12-12 2018-08-16 日商第一三共股份有限公司 Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (en) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd antibody or antibody functional fragment, polynucleotide, expression vector, host cells, method for producing an antibody of interest or antibody functional fragment and for producing an antibody-drug conjugate, antibody-drug conjugate, pharmaceutical composition , antitumor drug; and, method of treating a tumor.
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
JP7366745B2 (en) 2017-08-31 2023-10-23 第一三共株式会社 Improved manufacturing method for antibody-drug conjugates
KR102422860B1 (en) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 Novel method for preparing antibody-drug conjugates
TWI825098B (en) 2018-05-18 2023-12-11 德商葛萊高托普公司 Anti-muc1 antibody
CN109481691A (en) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425464T2 (en) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. POLYSACCHARIDE DERIVATIVE AND ACTIVE SUBSTANCE
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
ATE310538T1 (en) * 1996-04-15 2005-12-15 Asahi Chemical Ind MEDICINAL COMPLEXES CONTAINING TAXANE COMPOUNDS OR STEROIDS
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (en) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 Low contract photo-solidification cladding material, its prepn. method and use
KR100581443B1 (en) * 1998-05-22 2006-05-23 다이이찌 세이야꾸 가부시기가이샤 Drug Composites

Also Published As

Publication number Publication date
NO20041194L (en) 2004-03-19
TWI313609B (en) 2009-08-21
IL160148A0 (en) 2004-07-25
AU2002328093B2 (en) 2005-05-05
EP1418947A1 (en) 2004-05-19
CN100372570C (en) 2008-03-05
PL368319A1 (en) 2005-03-21
AR035137A1 (en) 2004-04-14
KR20040027972A (en) 2004-04-01
RU2004108141A (en) 2005-04-20
WO2003015826A1 (en) 2003-02-27
HUP0401351A3 (en) 2011-02-28
ZA200400917B (en) 2004-08-25
HUP0401351A2 (en) 2004-12-28
BR0212036A (en) 2004-08-17
RU2275913C2 (en) 2006-05-10
MXPA04001599A (en) 2004-07-08
CA2457056C (en) 2008-07-22
CN1545423A (en) 2004-11-10
NZ530947A (en) 2006-04-28
UA75450C2 (en) 2006-04-17

Similar Documents

Publication Publication Date Title
CA2457056A1 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
EP1430061A4 (en) Inclusion compound comprising cucurbituril derivatives as host molecule and pharmaceutical composition comprising the same
AU5783300A (en) Anilinoquinazolines as protein tyrosine kinase inhibitors
DE69912952D1 (en) Cyclosporine
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
CA2370245A1 (en) Enzyme-activated anti-tumor prodrug compounds
PL337719A1 (en) Pharmaceutic composition having enhanced anticarcinogenic activity and/or reduced side effects, containing an anticarcinogenic agwent and a derivative of hydroxamic acid
TR200200717T2 (en) Therapeutic quinazoline derivatives.
CA2269923A1 (en) Pharmaceutical compositions containing plasma protein
EP2364730A3 (en) Immunoglobulin preparations having increased stability
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
RU94042922A (en) Novel compounds, method for their production, pharmaceutical composition
CA2163706A1 (en) Amino Acid Derivatives of Paclitaxel
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
WO2001012233A3 (en) Sustained release formulation of a peptide
EP0394905A3 (en) Excitatory amino acid antagonists
GB0310919D0 (en) Pharmaceutical compositions
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
ATE249842T1 (en) TARGET DISHES MEDICINAL DELIVERY FOR ZULPHONAMIDE DERIVATIVES
TR199900336T2 (en) Tetrahydroquinoline derivatives as EAA antagonists.
WO2003086471A3 (en) Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin
DE60117247D1 (en) Phosphoramidate PRODRUGS
HK1055947A1 (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1H-Ä1,2,4Ütriazol, methods for producing them and pharmaceutical compositions containing them
EP2239270A3 (en) Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction
AU5992500A (en) Compound derived from an offset orf of the ice gene

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed